Firategrast(SB-683699)

Description: Firategrast (formerly known as SB-683699 or T-0047) is a novel, potent and orally bioavailable alpha4 beta1/alpha4 beta7 (alpha4beta1/alpha4beta7) integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS). This could decrease multiple sclerosis (MS) activity, but may compromise CNS immune surveillance. Firategrast treatment was associated with modest decreases in median CSF total, CD4, CD8 and CD19 lymphocyte counts. The generally small magnitude of decreases suggests that sufficient numbers of lymphocytes can access the subarachnoid space, preserving CNS immune surveillance.

References: Eur J Neurol. 2013 Jul; 20(7):1032-42